Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The Japan infusion therapy market was valued at USD 3.63 Billion in 2025 and is expected to grow at a CAGR of 6.40%, reaching USD 6.75 Billion by 2035. The market growth is driven by the rising chronic disease prevalence and increasing demand for home healthcare, coupled with regulatory approvals for advanced infusion devices across the region.
Base Year
Historical Period
Forecast Period
Regulatory approvals like KORU Medical’s FreedomEdge® drive adoption of home infusion therapies, expanding market reach and convenience.
Launches of oncology infusion therapies, such as LUNSUMIO®, increase hospital and clinic adoption, supporting intravenous segment growth.
Advanced formulations like Vyxeos® enhance treatment efficacy and patient adherence, stimulating market expansion and encouraging innovative therapy integration.
Compound Annual Growth Rate
6.4%
Value in USD Billion
2026-2035
*this image is indicative*
The market is witnessing steady growth, driven by an aging population and increasing prevalence of chronic diseases. Rising demand for home healthcare solutions and advanced infusion devices is encouraging hospitals and healthcare providers to adopt more efficient, patient-centric therapies. Additionally, technological innovations in infusion pumps and drug delivery systems are improving treatment accuracy and patient safety. Supportive government initiatives and growing awareness about the benefits of infusion therapy are further propelling market expansion, positioning Japan as a key region for infusion therapy adoption in the Asia-Pacific healthcare sector. The market is expected to grow at a CAGR of 6.40% during the forecast period of 2026-2035 and attain a market value of USD 6.75 Billion by 2035.
Regulatory Approvals and Technological Innovations Boost Market Growth
Rising demand for home healthcare solutions and growing chronic disease prevalence are key drivers of the market. For instance, in July 2024, KORU Medical Systems received regulatory clearance in Japan for its FreedomEdge® Infusion System, enabling delivery of therapies like Subcutaneous Immunoglobulin (SCIg) and treatments for rare diseases directly to patients’ homes. The portable and user-friendly system enhances patient convenience and safety, promoting wider adoption of home infusion therapies. This development is expected to accelerate market growth throughout the forecast period.
The market is driven by regulatory approvals and innovative oncology treatments.
Expansion of Intravenous Oncology Therapies to Boost Market Growth
The launch of LUNSUMIO® (mosunetuzumab) in Japan for relapsed or refractory follicular lymphoma demonstrates a growing focus on intravenous oncology treatments. Fixed-duration infusion therapies reduce patient burden and improve adherence, driving adoption in hospitals and specialty clinics. Rising cancer prevalence and demand for advanced infusion solutions are encouraging healthcare providers to integrate these therapies, supporting market growth. Innovations in oncology infusion are poised to expand the intravenous segment, contributing significantly to the overall infusion therapy market during the forecast period.
Oncology Infusion Therapy Launches Driving Japan Infusion Therapy Market Demand
Growing demand for effective cancer treatments and technological innovations in drug delivery are major market trends. For instance, in May 2024, Nippon Shinyaku launched Vyxeos® Combination for I.V. Injection for high-risk acute myeloid leukemia, approved by Japan’s Ministry of Health in March 2024. The liposomal formulation enables controlled drug release, improving efficacy and reducing toxicity. Such advancements in intravenous oncology therapies are expected to drive hospital and clinic adoption, expanding the infusion therapy segment and contributing to significant market development during the forecast period.
Antibiotic/Antiviral Segment to Lead the Market by Therapy Type
The antibiotic/antiviral segment held the largest share of Japan’s infusion therapy market, accounting for 26% of total revenue. This segment is likely to maintain its dominance due to the high prevalence of infectious diseases and growing demand for effective intravenous treatments. Hospitals and clinics prioritize the timely administration of these therapies, ensuring rapid patient recovery. Continuous development of novel antibiotics and antiviral formulations, along with increasing awareness of infection control, further supports this segment’s leading role in market growth during the forecast period.
The key features of the market report comprise funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Founded in 1839, B. Braun SE is headquartered in Melsungen, Germany. It’s a Japan leader in medical devices and pharmaceuticals. Its broad product portfolio includes infusion therapy (infusion pumps, solutions, IV access), surgery and orthopedics, anaesthesia care, extracorporeal blood treatment, wound management, and hospital consumables. The company operates through divisions such as Hospital Care, Aesculap (surgical instruments), Avitum (dialysis), supplying hospitals, clinics, and home care.
Founded in 1949, Medtronic plc is a medical technology company headquartered in Dublin, Ireland, with operational headquarters in the United States. It develops and commercializes device-based therapies, including cardiovascular and vascular systems (pacemakers, defibrillators, stents), neuroscience (spinal stimulators, brain modulation), medical-surgical devices (surgical tools, robotics), and diabetes care. Medtronic serves hospitals, physicians, and integrated healthcare systems worldwide.
Founded in 1897, Becton, Dickinson and Company (BD) is headquartered in Franklin Lakes, New Jersey, USA. BD is a major player in medical technology and devices, offering products across three divisions: BD Medical, BD Life Sciences, and BD Interventional. Its portfolio includes infusion systems (large volume and syringe pumps, infusion sets), drug delivery devices, diagnostics, and safety-engineered medical equipment. BD serves hospitals, outpatient care, and home health markets Japanly.
Established in 1984, ICU Medical is headquartered in San Clemente, California, USA. It specializes in infusion therapy and related critical care products. Its offerings include IV smart pumps, ambulatory and large-volume infusion pumps, IV solutions and sets, needle-free connectors, closed system drug handling systems, anesthesia products, patient monitoring, and respiratory and temperature management systems. ICU supplies acute care hospitals, clinics, and alternative care sites.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Baxter AG, Terumo Medical Corporation, Fresenius Kabi, and Cardinal Health.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product
Market Breakup by Indication
Market Breakup by Therapy Type
Market Breakup by End User
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Indication |
|
| Breakup by Therapy Type |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share